All In Biotech

Drug Trial Radar · NCT05348122

A Study of TG103 Injection in Type 2 Diabetes Subjects

A Multicenter, Randomized, Double-blind, Placebo-controlled,Dulaglutide-controlled Phase Ⅱ Trial Exploring Optimal Dosing Regimen for TG103 Injection Monotherapy in Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Jun 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

240

Planned (sponsor's estimate)

Start

Jun 15, 2022

Primary completion

Nov 1, 2023

Study completion Nov 1, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • TG103,Q2WDrug

    TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

  • TG103,QWDrug

    TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

  • Placebo,Q2WDrug

    Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

  • Placebo,QWDrug

    Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

  • Dulaglutide,QWDrug

    Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17Time frame: Baseline through Day 113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gao Huanhuan

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.